Hoechst Austria, the German chemical and pharmaceutical company's Vienna-based unit, expects a marked increase in drug-sector business in 1994 through the South-East Europe Business Unit, taken over in 1993.
The new marketing region covers Austria, the Czech Republic, Slovakia, Hungary, Slovenia and Croatia. It is understood that Switzerland is also to be included in the region for reasons of cost-efficiency. The company says that medium-term drug sales growth potential in south east Europe is between 10% and 15% annually.
In 1994, sales will increase to 350 million Austrian schillings ($30.15 million) from 281 million schillings the previous year. Planned growth for the entire business unit is some 6% to 1.8 billion schillings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze